Clinical Trial Finder

Inclusion Criteria:

1. Cerebral relapse of primary CNS lymphoma (any line) 2. Pathological diagnosis of diffuse large B cell lymphoma (or cytological diagnosis in the CSF or in the vitreous) at initial diagnosis (not mandatory at the time of the present relapse) 3. Absence of any systemic involvement confirmed by full body CT scan and/or FDG-PET scan. 4. Age≥18 years. 5. HD-MTX based chemotherapy in first line treatment, with complete response lasting at least 6 months after the end of the 1st line treatment. 6. No administration of other anticancer therapy within the 3 weeks prior to inclusion. 7. Karnofsky performance status (KPS) ≥ 50. 8. Adequate haematological, renal and hepatic function (adequate Laboratory Parameters within 21 days): 1. Absolute neutrophil count (ANC) >1000/mm3. 2. Platelets > 100,000/mm3 independent of transfusion support. 3. Alanine aminotransferase and aspartate aminotransferase ≤ 3 x upper limit of normal (ULN) and/or total bilirubin ≤ 1,5x ULN, unless related to Gilbert's or Meulengracht disease. 4. Estimated Glomerular Filtration Rate ≥ 60 mL/min/1.73m2) (MDRD) 9. All non-hematological adverse events (AEs) related to prior therapy completely resolved or improved to Grade 1-2 (except for alopecia or fatigue). 10. Written informed consent, which could be signed by the trustworthy person or close relatives in case the neurologic status of the patient does not allow him to sign. In case the patient is unable to sign the consent at baseline, but his neurological status improves during the treatment, he will be asked to give his written informed "follow-up" consent.

Exclusion Criteria:

1. Positive HIV serology. 2. Active viral infection with Hepatitis B or C virus. 3. Preexisting immunodeficiency (organ transplant recipient) 4. Relevant congestive heart failure interfering with hydration. 5. Isolated CNS relapse of systemic non-Hodgkin's lymphoma (NHL) 6. Pregnancy or lactation. An effective contraception is mandatory for patients (men and women of childbearing potential) all along the study participation and during at least 6 months after the end of MTX. Men must not donate sperm all along the study participation and during at least 6 months after the end of MTX. 7. Third space (i.e. pleural effusion, ascites, extended oedema). 8. Obesity (body mass index >30 kg/m2). 9. Any other active malignancy, except basocellular carcinoma and non-invasive cervix cancer. 10. Absolute contraindication to MTX or leucovorin. 11. Previous use of carboxypeptidase for delayed MTX excretion and kidney dysfunction after HD-MTX. 12. No social security affiliation. 13. Persons under legal protection (tutorship or curatorship) or safety measure. 14. Participation in any other clinical trial (Jardé 1 and 2) either 1 month prior to or during this study.

Open-label multicenter Phase I dose finding trial based on 3+3 escalation design. The phase I will follow a standard "3+3" dose level escalation design with reduced time interval of HD-MTX injections at fixed dose of HD-MTX to establish the minimum tolerated time interval. HD-MTX (methotrexate) is administered intravenously at the dose 3.5 g/m² (body surface area capped at 2 m2) over 2 to 3 hours, followed at H24 by glucarpidase with a 3 different MTX administration intervals: 8 days, 6 days, and 5 days. Treatments will be continued for a maximum of 6 injections until disease progression, unacceptable toxicity, or investigator's/patient's decision. Three dose levels could be explored under toxicity restrictions, where the dose combination for each cohort of three subjects will be determined by 3+3 escalation rule. Three schedule dose levels will be : every 8 days, every 6 days and every 5 days. The starting schedule dose of HD-MTX will be one administration of HD-MTX every 8 days for 6 injections. Dose of MTX will be fixed and will not be modified. No skipping of the dose level will be allowed. No intra-patient dose escalation is allowed. The DLT evaluation period begins with the first dose of methotrexate and ends at the beginning of the 25th day after the first MTX infusion.

Arms

Experimental: CPG2

6 infusions of glucarpidase

Interventions

Drug: - Glucarpidase

Glucarpidase (CPG2) Dose: 2000 U (2 vials of 1000 U per dose) 5 minutes-intravenous administration 24 hours after each Methotrexate infusion (i.e. 6 times in the whole protocol)

Drug: - Methotrexate (MTX)

MTX will be administred 6 times during the protocol, at a variable interval of 8, 6 or 5 days. It will be administrated in a 2 to 3-hour IV infusion, at the dose of 3.5 g/m2 (body surface area capped at 2 m2). Each MTX administration will be preceded by a prehydration and will be followed by a posthydration